Drug Trial Radar · NCT06154837
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
127
Actual
Start
Nov 27, 2023
Primary completion
Dec 16, 2026
Study completion Dec 16, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995BDrug
GSK3862995B will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 36 weeks
- Part B: Number of Participants with AEs and SAEsTime frame: Up to 48 weeks
- Part A: Number of Participants with Clinically significant changes in laboratory valuesTime frame: Up to 28 weeks
- Part A: Number of Participants with Clinically Significant Change in vital signsTime frame: Up to 28 weeks
- Part A: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) ParametersTime frame: Up to 28 weeks
- Part B: Number of Participants with Clinically significant changes in laboratory values (haematology, chemistry and urinalysis)Time frame: Up to 42 weeks
- Part B: Number of Participants with Clinically Significant Change in vital signsTime frame: Up to 42 weeks
- Part B: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) ParametersTime frame: Up to 42 weeks
Locations
31 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Yuma, Arizona
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Orange City, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Shelby, North Carolina
GSK Investigational Site
Medford, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Rock Hill, South Carolina
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Ahrensburg, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Dresden, Germany
GSK Investigational Site
Frankfurt, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Leipzig, Germany
GSK Investigational Site
Lübeck, Germany
GSK Investigational Site
Mainz, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Barnsley, United Kingdom
GSK Investigational Site
Cambridge, United Kingdom
GSK Investigational Site
Cannock, United Kingdom
GSK Investigational Site
London, United Kingdom
GSK Investigational Site
Manchester, United Kingdom
GSK Investigational Site
West Yorkshire, United Kingdom
GSK Investigational Site
Blackpool, Lancashire, United Kingdom
GSK Investigational Site
Harrow, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.